Literature DB >> 12879422

Inflammatory mediators promote strong sickle cell adherence to endothelium under venular flow conditions.

Paula S Walmet1, James R Eckman, Timothy M Wick.   

Abstract

Adherence of sickle erythrocytes to endothelium in venules is thought to initiate or propagate vaso-occlusive episodes. Because of blood shear forces with normal microvascular flow, adherence in post-capillary venules requires binding via high-affinity receptor-mediated pathways. Microvascular flow in sickle patients is episodic, even in asymptomatic patients, so adherence may also occur at low shear not requiring high-affinity binding. Sickle cell binding to endothelium was quantified under flow or static incubation with unusually large vWF, thrombospondin, alpha(4)beta(1)/VCAM-1 or alpha(4)beta(1)/fibronectin (FN). Adherence under flow at 0.5 dyne/cm(2) shear stress leads to the greatest number of adherent sickle cells. Adherence under flow at 1.0 dyne/cm(2) leads to the strongest adherence. Static incubation conditions promote weak adherence of low numbers of sickle cells to endothelium. Following attachment at 1.0 dyne/cm(2), adherence strength was 2.5 +/- 0.1 or 2.6 +/- 0.2 dynes/cm(2) for alpha(4)beta(1)/VCAM-1 or alpha(4)beta(1)/FN pathways, a level 50% greater than adherence strength mediated by thrombospondin or ULvWF (1.7 +/- 0.08 or 1.6 +/- 0.07 dynes/cm(2), respectively). Sickle cell adhesion promoted by simultaneous activation of alpha(4)beta(1)/VCAM-1 and alpha(4)beta(1)/FN pathways is the strongest at 6.2 +/- 0.2 dynes/cm(2) and adherent red cells resist detachment shear stresses up to 10 dynes/cm(2). These data demonstrate that sickle cell adhesion to endothelium is regulated both by receptor/ligand affinity and flow conditions. Thus, both microvascular flow conditions and receptor-ligand interactions may regulate sickle cell adherence in vivo. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879422     DOI: 10.1002/ajh.10360

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  11 in total

1.  Evaluation of the effect of expansion and shear stress on a self-assembled endothelium mimicking nanomatrix coating for drug eluting stents in vitro and in vivo.

Authors:  Adinarayana Andukuri; IlJae Min; Patrick Hwang; Grant Alexander; Lauren E Marshall; Joel L Berry; Timothy M Wick; Yoon Ki Joung; Young-Sup Yoon; Brigitta C Brott; Dong Keun Han; Ho-Wook Jun
Journal:  Biofabrication       Date:  2014-07-22       Impact factor: 9.954

2.  Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1.

Authors:  Daniel A Dworkis; Elizabeth S Klings; Nadia Solovieff; Guihua Li; Jacqueline N Milton; Stephen W Hartley; Efthymia Melista; Jason Parente; Paola Sebastiani; Martin H Steinberg; Clinton T Baldwin
Journal:  Am J Hematol       Date:  2011-02       Impact factor: 10.047

3.  Activation state of alpha4beta1 integrin on sickle red blood cells is linked to the duffy antigen receptor for chemokines (DARC) expression.

Authors:  Marie-Claude Durpès; Marie-Dominique Hardy-Dessources; Wassim El Nemer; Julien Picot; Nathalie Lemonne; Jacques Elion; Monique Decastel
Journal:  J Biol Chem       Date:  2010-11-18       Impact factor: 5.157

4.  Endothelial glycocalyx regulates cytoadherence in Plasmodium falciparum malaria.

Authors:  Viola Introini; Antonio Carciati; Giovanna Tomaiuolo; Pietro Cicuta; Stefano Guido
Journal:  J R Soc Interface       Date:  2018-12-21       Impact factor: 4.118

5.  The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.

Authors:  Junmei Chen; William E Hobbs; Jennie Le; Peter J Lenting; Philip G de Groot; José A López
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

Review 6.  Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.

Authors:  Gregory J Kato; Mark T Gladwin
Journal:  JAMA       Date:  2008-12-10       Impact factor: 56.272

7.  Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis.

Authors:  Jeffrey Glassberg; Adeeb H Rahman; Mohammad Zafar; Caroline Cromwell; Alexa Punzalan; Juan Jose Badimon; Louis Aledort
Journal:  J Immunol Methods       Date:  2017-07-29       Impact factor: 2.303

8.  Novel Multifunctional Nanomatrix Reduces Inflammation in Dynamic Conditions in Vitro and Dilates Arteries ex Vivo.

Authors:  Grant C Alexander; Jeremy B Vines; Patrick Hwang; Teayoun Kim; Jeong-a Kim; Brigitta C Brott; Young-Sup Yoon; Ho-Wook Jun
Journal:  ACS Appl Mater Interfaces       Date:  2016-02-17       Impact factor: 9.229

9.  Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia.

Authors:  Ted Wun; Lori Styles; Laura DeCastro; Marilyn J Telen; Frans Kuypers; Anthony Cheung; William Kramer; Henry Flanner; Seungshin Rhee; John L Magnani; Helen Thackray
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

10.  Altered phenotype and gene transcription in endothelial cells, induced by Plasmodium falciparum-infected red blood cells: pathogenic or protective?

Authors:  Srabasti J Chakravorty; Celine Carret; Gerard B Nash; Al Ivens; Tadge Szestak; Alister G Craig
Journal:  Int J Parasitol       Date:  2007-02-20       Impact factor: 3.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.